T. Lehtinen

Articles by T. Lehtinen

Rituximab as a Single Agent and in Combination With Interferon Alfa-2a as Treatment of Untreated and First-Relapse Follicular or Other Low-Grade Lymphomas: A Randomized Phase II Study (M 39035)

ByE. Kimby,C. Geisler,H. Hagberg,H. Holte,T. Lehtinen,C. Sundström

March 1st 2001

Rituximab (Rituxan) is approved for use in patients with relapsed and refractory follicular lymphoma. Considering the immune modulating effect of interferon alfa-2a (IFN [Roferon-A]) and its efficacy as a single agent in follicular lymphoma, a

Latest Updated Articles

Rituximab as a Single Agent and in Combination With Interferon Alfa-2a as Treatment of Untreated and First-Relapse Follicular or Other Low-Grade Lymphomas: A Randomized Phase II Study (M 39035)
March 1st 2001

Trending on CancerNetwork

Achieving a “Functional Cure” With Multiple Myeloma Therapy

ASCO Updates 340B Policy Statement to Expand Access, Improve Transparency

FDA Accepts sNDA for Taletrectinib in ROS1-Positive NSCLC

Bridging the Gap: Overcoming Institutional Barriers to Exercise Oncology

130 Sacituzumab Govitecan (SG) + Pembrolizumab (Pembro) Vs Chemotherapy (Chemo) + Pembro in Previously Untreated PD-L1–Positive Advanced Triple-Negative Breast Cancer (TNBC): Primary Results From the Randomized Phase 3 ASCENT-04/KEYNOTE-D19 Study